Tenapanor
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis, Constipation
Trial Timeline
Jun 1, 2025 → Jun 30, 2027
NCT ID
NCT06810167About Tenapanor
Tenapanor is a phase 3 stage product being developed by Ardelyx for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06810167. Target conditions include Cystic Fibrosis, Constipation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06810167 | Phase 3 | Recruiting |
| NCT05995899 | Approved | Completed |
| NCT06203444 | Phase 1 | Completed |
| NCT05905926 | Phase 3 | Recruiting |
| NCT04549597 | Approved | Completed |
| NCT02727751 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis